Research Participant Registry Join Now!
Immune System/Infections

If you are interested in hearing more about one or more of the studies listed below, and you are already a Registry participant, please contact the Research Participant Registry at 1-866-438-8230 or via e-mail

REPRIEVE Heart Study University of Pittsburgh PRO15010395
Participants are invited to join a study about heart disease prevention in people with HIV. Eligible participants are between 40-75 years old, have been on retroviral therapy (ART) for at least 6 months, have a CD4+ cell count>100, have no history of cardiovascular disease, and are not currently using a statin drug. Study participation will last approximately 72 months. Compensation provided.

Rituximab in Myasthenia Gravis University of Pittsburgh EXT14010027
The purpose of this study is to learn if rituximab is a safe and effective drug for people with Myasthenia Gravis (MG) who are on prednisone. It will also help determine if rituximab can help people take less, or possibly discontinue, prednisone. Eligible participants are 21 to 90 years old, have a diagnosis of generalized MG and must be taking a stable dose of prednisone. Compensation provided.

Pemphigus Vulgaris Study Quorum Review, Inc. 28302/3
Do you have pemphigus vulgaris? If so, you may be eligible to participate in a study to test an investigational drug to see if it will work to help with pemphigus vulgaris symptoms. Participation requires 18 study visits. The study will last over 1 year. Participants will be compensated.

Pulmonary Study - African American Men and Women Ages 35-65 University of Pittsburgh PRO10060177
African American men and women between the ages of 35 and 65 years old needed for lung function study. Participants will complete a questionnaire, participate in pulmonary function testing, provide a blood specimen, provide a sputum specimen, and have fat tissue biopsied (optional). Men must be current or former smokers and women must be currently smoking. Compensation provided.

ACTG A5320 PRO14010146
Have you been in a Hepatitis C treatment research study within the past year? If so, you may be eligible to participate in a study where your experience can help researchers develop better ways to treat Hepatitis C. Study visits are twice a year, plus a visit before starting any new Hepatitis C treatment. No medications are provided by this study. Parking/travel-related expenses reimbursed.

ACTG A5314 PRO13090071
Are you at least 40 years of age? Are you HIV-1 positive? People who have an undetectable HIV viral load while on HIV medications for the past 6 months, have a CD4 cell count of at least 400, and have active heart disease or are at risk for heart disease may be eligible to participate in this study that will look at the effects of a medication on inflammation and heart health in those with HIV.

Rifaximin and HIV PRO13060212
Are you infected with HIV, taking anti-retroviral drugs, and have a very low HIV-1 RNA viral load (the amount of HIV in your blood)? If so, you may be eligible to participate in a study to see if rifaximin, an antibiotic that works in the intestines, can reduce bacteria-related inflammation in people with HIV. Participation will last about 16-18 weeks. Compensation is provided.

ENT Research – Ragweed Study PRO13040368A
Do you have ragweed allergy? Are you a relatively healthy adult between the ages of 18 and 50? If so, you may be eligible to participate in a study to determine if allergic rhinitis (nasal allergy) increases the rate of blood-flow in the lining of the middle ear. This study requires three visits to Children’s Hospital of Pittsburgh. Compensation provided.

CHIC II Study PRO11120183
Are you a generally healthy woman between the ages of 18 and 34 years old who has regular periods? If so, and if you are not pregnant or currently using hormones for birth control, you may be eligible to participate in a study to better understand how birth control affects the immune cells within the reproductive tract. Compensation is provided.

HIV Prevention Research Registry PRO11110371
Are you interested in learning about HIV prevention research studies taking place at the University of Pittsburgh and UPMC? If so, you can join the HIV Prevention Research Registry. HIV prevention registry members may be contacted by registry staff members about studies for which they appear to qualify. Eligible participants are ages 18 and older.

ACTG A5308 PRO12100377
Are you age 18 or older and HIV-infected? Has your viral load been less than 500 for the past 2 years? If so, and if you have never taken HIV medications, you may be eligible to participate in a study to see if taking HIV medication reduces immune activation in people who have HIV but show no symptoms. All participants will receive Complera through the study for 1-2 years.

ACTG A5286 PRO11020001
Are you HIV positive and between the ages of 18 and 65? If so, you may be eligible to participate in a study to see whether a certain drug prevents the persistent inflammation that is present in many people with HIV. Participants must have been taking anti-HIV medications for about 2 years or longer, have had an undetectable viral load for the past year, and have a low white blood cell count.

ACTG A5298 PRO11090510
Are you a HIV-infected man who has sex with other men and are aged 27 years or older? If so, you may be eligible to participate in a study to determine the acceptability of procedures and treatments associated with anal HPV infection. The participants in this study will have anal HPV DNA testing, oral HPV DNA testing, high-resolution anoscopies and other tests. Travel costs will be reimbursed.

To find out about the Research Participant Registry and opportunities to participate in research studies (or to withdraw from the Registry),
contact or call 1-866-438-8230.
This website is maintained by the Clinical and Translational Science Institute.
If you have any technical difficulty please submit your help request here.
© Office of the Senior Vice Chancellor for the Health Sciences, University of Pittsburgh. All rights reserved.